BACKGROUND:Prostaglandin E(2) (PGE(2)) has been suggested to play an important role in the pathogenesis of migraine. In the present experiment we investigated if an intravenous infusion of PGE(2) would induce migraine-like attacks in patients with migraine. METHODS:Twelve patients with migraine without aura were randomly allocated to receive 0.4 µg/kg/min PGE(2) (Prostin(®)E2, dinoprostone) or placebo over 25 minutes in a two-way, crossover study. Headache intensity was recorded on a verbal rating scale, middle cerebral artery blood flow velocity (V(MCA)) was measured by transcranial Doppler (TCD) and diameter of the superficial temporal artery (STA) was obtained by c-series scan (Dermascan C). RESULTS: In total, nine migraine patients (75%) experienced migraine-like attacks after PGE(2) compared to none after placebo (p = 0.004). Seven out of 9 (58%) patients reported the migraine-like attacks during the immediate phase (0-90 min) (p = 0.016). Only two patients experienced the delayed migraine-like attacks several hours after the PGE(2) infusion stop (p = 0.500). The V(MCA) decreased during the PGE(2) infusion (p = 0.005) but there was no significant dilatation of the STA (p = 0.850). CONCLUSION: The migraine-like attacks during, and immediately after, the PGE(2) infusion contrast with those found in previous provocation studies, in which the other pharmacological compounds triggered the delayed migraine-like attacks several hours after the infusion. We suggest that PGE(2) may be one of the important final products involved in the generation of migraine attacks.
RCT Entities:
BACKGROUND:Prostaglandin E(2) (PGE(2)) has been suggested to play an important role in the pathogenesis of migraine. In the present experiment we investigated if an intravenous infusion of PGE(2) would induce migraine-like attacks in patients with migraine. METHODS: Twelve patients with migraine without aura were randomly allocated to receive 0.4 µg/kg/min PGE(2) (Prostin(®)E2, dinoprostone) or placebo over 25 minutes in a two-way, crossover study. Headache intensity was recorded on a verbal rating scale, middle cerebral artery blood flow velocity (V(MCA)) was measured by transcranial Doppler (TCD) and diameter of the superficial temporal artery (STA) was obtained by c-series scan (Dermascan C). RESULTS: In total, nine migrainepatients (75%) experienced migraine-like attacks after PGE(2) compared to none after placebo (p = 0.004). Seven out of 9 (58%) patients reported the migraine-like attacks during the immediate phase (0-90 min) (p = 0.016). Only two patients experienced the delayed migraine-like attacks several hours after the PGE(2) infusion stop (p = 0.500). The V(MCA) decreased during the PGE(2) infusion (p = 0.005) but there was no significant dilatation of the STA (p = 0.850). CONCLUSION: The migraine-like attacks during, and immediately after, the PGE(2) infusion contrast with those found in previous provocation studies, in which the other pharmacological compounds triggered the delayed migraine-like attacks several hours after the infusion. We suggest that PGE(2) may be one of the important final products involved in the generation of migraine attacks.
Authors: Bizu Gelaye; Gloria T Larrabure-Torrealva; Chunfang Qiu; Miguel Angel Luque-Fernandez; B Lee Peterlin; Sixto E Sanchez; Michelle A Williams Journal: Headache Date: 2015-04-22 Impact factor: 5.887
Authors: Christopher E Ramsden; Anthony F Domenichiello; Zhi-Xin Yuan; Matthew R Sapio; Gregory S Keyes; Santosh K Mishra; Jacklyn R Gross; Sharon Majchrzak-Hong; Daisy Zamora; Mark S Horowitz; John M Davis; Alexander V Sorokin; Amit Dey; Danielle M LaPaglia; Joshua J Wheeler; Michael R Vasko; Nehal N Mehta; Andrew J Mannes; Michael J Iadarola Journal: Sci Signal Date: 2017-08-22 Impact factor: 8.192
Authors: Erika F H Saunders; Christopher E Ramsden; Mostafa S Sherazy; Alan J Gelenberg; John M Davis; Stanley I Rapoport Journal: J Clin Psychiatry Date: 2016-10 Impact factor: 4.384
Authors: Peter J Goadsby; Philip R Holland; Margarida Martins-Oliveira; Jan Hoffmann; Christoph Schankin; Simon Akerman Journal: Physiol Rev Date: 2017-04 Impact factor: 37.312
Authors: John Douglas Mann; Keturah R Faurot; Beth MacIntosh; Olafur S Palsson; Chirayath M Suchindran; Susan Ann Gaylord; Chanee Lynch; Angela Johnston; Kristen Maiden; David A Barrow; Joseph R Hibbeln; Christopher E Ramsden Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2017-11-16 Impact factor: 4.006